T-cell-based Immunotheranostics for personalized Cancer Therapy
Standard cancer therapies including radio- and chemotherapy are often not sufficient to effectively defeat tumor diseases. Accordingly, personalized therapies are becoming more prominent in the field of modern cancer therapies. The overall aim of such strategies is to individually adapt treatment regimen to each patient in order to maximize therapy response and improve overall survival.
The tandem of Dr. Claudia Arndt (Scientist) and Dr. Frederick Fasslrinner (Clinician) is focusing on the development of personalized cellular immunotheranostics for the diagnosis and therapy of acute myeloid leukemia (AML); a common hematological malignancy. By using our switchable UniCAR T-cell technology, we aim to combine cellular immunotherapy, local radioimmunotherapy and optical imaging as an individual treatment modality.
Funding and support
Our interdisciplinary research group of clinicians, chemists and biologists is supported by the Mildred-Scheel Nachwuchszentrum (https://tu-dresden.de/med/mf/msnz)/ Deutsche Krebshilfe and hosted by the Institute of Radiopharmaceutical Cancer Research, Department of Radioimmunology. Our research work is performed at the Helmholtz-Zentrum Dresden-Rossendorf as well as at the University Hospital Carl Gustav Carus Dresden.